2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-138454
    MEG hemisulfate 3979-00-8 98%
    MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC50s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock.
    MEG hemisulfate
  • HY-138572
    Fanetizole 79069-94-6 98%
    Fanetizole is an anti-inflammatory agent. Fanetizole can be used for inflammatory diseases research.
    Fanetizole
  • HY-138623
    GSK789 2540591-06-6 98%
    GSK789, a chemical probe, is an effective, cell-permeable, and highly selective inhibitor of the BET family first bromodomain (BD1), with antitumor and immunomodulatory effects
    GSK789
  • HY-138651
    PAB-Val-Lys-Boc 1432969-86-2
    PAB-Val-Lys-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) for stimulating an immune response.
    PAB-Val-Lys-Boc
  • HY-138871
    cPLA2α-IN-derivative 1 1233706-89-2 98%
    cPLA2α-IN-derivative 1 is an inactive alcohol derivative of a highly potent Cytosolic phospholipase A2α (cPLA2α) inhibitor.
    cPLA2α-IN-derivative 1
  • HY-138942
    PF-06427878 1809064-23-0 98%
    PF-06427878 is an orally active, selective liver-targeted diacylglycerol acyltransferase 2 (DGAT2) inhibitor with IC50s of 99 nM and 202 nM for human and rat DGAT2, respectively. PF-06427878 shows greater than 470-fold selectivity for DGAT2 over DGAT1, MGAT1, MGAT2 and MGAT3. PF-06427878 can improve liver steatosis and function. PF-06427878 can be used for the study of nonalcoholic fatty liver diseases.
    PF-06427878
  • HY-138951
    AY77 1835734-92-3 98%
    AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC50 of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca2+ release.
    AY77
  • HY-138990
    GK563 2351820-19-2 98%
    GK563 is a selective Ca2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes.
    GK563
  • HY-139019
    ACAT-IN-2 199984-55-9 98%
    ACAT-IN-2 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription.
    ACAT-IN-2
  • HY-139020
    ACAT-IN-3 454203-25-9 98%
    ACAT-IN-3 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-3 inhibits NF-κB mediated transcription.
    ACAT-IN-3
  • HY-139021
    ACAT-IN-4 454203-56-6 98%
    ACAT-IN-4 (Example 208) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 inhibits NF-κB mediated transcription.
    ACAT-IN-4
  • HY-139022
    ACAT-IN-5 199983-93-2 98%
    ACAT-IN-5 (example 19) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-5 inhibits NF-κB mediated transcription.
    ACAT-IN-5
  • HY-139023
    ACAT-IN-6 454203-45-3 98%
    ACAT-IN-6 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 200. ACAT-IN-6 potently inhibits NF-κB mediated transcription.
    ACAT-IN-6
  • HY-139024
    ACAT-IN-7 199984-38-8 98%
    ACAT-IN-7 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-7 inhibits NF-κB mediated transcription.
    ACAT-IN-7
  • HY-139025
    ACAT-IN-8 199984-35-5 98%
    ACAT-IN-8 (example 206) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-8 inhibits NF-κB mediated transcription.
    ACAT-IN-8
  • HY-139026
    ACAT-IN-9 199984-40-2 98%
    ACAT-IN-9 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription.
    ACAT-IN-9
  • HY-139027
    ACAT-IN-10 454203-40-8 98%
    ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription.
    ACAT-IN-10
  • HY-139043
    6-B345TTQ 297157-87-0 98%
    6-B345TTQ is an α4 integrin inhibitor that inhibits α4-Leupaxin interaction. 6-B345TTQ can be used in inflammation research.
    6-B345TTQ
  • HY-139055
    NCTT-956 438575-88-3 98%
    NCTT-956 is a very effective platelet 12-lipoxygenase (12-LOX) activity-specific inhibitor.
    NCTT-956
  • HY-139112
    Leukotriene B4 dimethyl amide 83024-92-4 98%
    Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology.
    Leukotriene B4 dimethyl amide
Cat. No. Product Name / Synonyms Application Reactivity